PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets
Research in Pharmaceutical Sciences · 2026-03 · 21 (2) · 236-250
DOI: 10.4103/rps.rps_82_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 24.04.2026. Verfasst von Saba Feghhi-Najafabadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Pasteur Institute of Iran, Tehran, I.R. Iran. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: The PD-1/PD-L1 immune checkpoint pathway inhibits T cell function, allowing tumors to escape immune responses. This study aimed to reprogram this inhibitory signaling using a PD- 1:CD28 switch receptor (SR) to convert inhibitory signaling into a co-stimulatory signal and to assess its effects on the function of CD4 + and CD8 + T cells. Experimental approach: PBMCs isolated from both sources were retrovirally transduced with PD-1:CD28 SR. Intracellular expression of cytokines, including IFN-γ, IL-4, IL-10, as well as the surface CD25 in CD4 + and CD8 + T cells, and the rate of cell apoptosis during engineering and exposure to target cells were assessed. Findings/Results: Both buffy coat (BC) and whole blood showed comparable transduction efficiency (21.4% versus 18.5%, respectively), but BC yielded nearly double the number of viable PBMCs per 50 mL. Upon stimulation and co-culture with target cells, CD4 + SR T cells produced significantly higher levels of IFN-γ, IL-4, and IL-10 compared to CD8 + SR T cells. These cytokines also significantly increased in co-culture supernatants exposed to PD-L1 + cells. No significant differences were found in CD4/CD8 ratios, CD25 expression, or cytokine profiles between PBMC sources. However, BC-derived T cells showed higher apoptosis rates during co-culture. Conclusion and implications: BC can be a practical and effective source of PBMCs for T cell engineering. These findings underscore the SR signaling in the activation of CD4 + T cells that may impact the activation of CD8 + T cells, which is essential for effective tumor eradication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, Pasteur Institute of Iran, Tehran, I.R. Iran.
- Student Research Committee, Pasteur Institute of Iran, Tehran, I.R. Iran.
- National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, I.R. Iran.
- Department of Medical Biotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, I.R. Iran.
- Food and Drug Laboratory Research Center (FDLRC), Food and Drug Administration, Iran Ministry of Health and Medical Education, Tehran. I.R. Iran.
- Department of Molecular Virology, Pasteur Institute of Iran, Tehran, I.R. Iran.
Zitieren
APA
Feghhi-Najafabadi, S., Riazi-Rad, F., Shokrgozar, M. A., Abdoli, S., Taheri, F. H., Arashkia, A., & Sharifzadeh, Z. (2026). PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets. Research in Pharmaceutical Sciences, 21(2), 236-250. https://doi.org/10.4103/rps.rps_82_25
Vancouver
Feghhi-Najafabadi S, Riazi-Rad F, Shokrgozar MA, Abdoli S, Taheri FH, Arashkia A, et al. PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets. Research in Pharmaceutical Sciences. 2026;21(2):236-250. doi:10.4103/rps.rps_82_25
BibTeX
@article{FeghhiNajafabadi2026,
author = {Feghhi-Najafabadi, Saba and Riazi-Rad, Farhad and Shokrgozar, Mohammad Ali and Abdoli, Shahriyar and Taheri, Fatemeh Hajari and Arashkia, Arash and Sharifzadeh, Zahra},
title = {PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {2},
pages = {236--250},
doi = {10.4103/rps.rps_82_25}
}
EUVIMED